

## CONTENTS

Bratisl Lek Listy 2004; 105 (4)



**12<sup>th</sup> ALPE ADRIA  
CARDIOLOGY  
MEETING**

**April 29 - May 1, 2004  
Cividale del Friuli, Italy**

Dear colleagues,

On behalf of the Scientific Committee I wish to invite you to attend the 12<sup>th</sup> Alpe Adria Cardiology Meeting, which comes back to Italy for the second time.

The choice of the meeting venue for this edition fell on the town of Cividale del Friuli, a town of historic importance in its role as “hinge” between North and South, East and West. Defended by the banks of the Natisone River, Cividale was marked and enriched from the passage of Longobards and Franks, and is today the venue of the Mittelfest cultural Festival, which draws together artists from Alpe Adria regions.

The choice of the date fell on the historic 1<sup>st</sup> May 2004, the EU enlargement date confirmed by the European Council. From that day, Cyprus, the *Czech Republic*, Estonia, *Hungary*, Latvia, Lithuania, Malta, Poland, *Slovakia*, and *Slovenia* will be formally EU members.

I expect this twelfth edition to be entirely successful. I do look forward to meeting you personally in Cividale, and promise you a high scientific event as well as a pleasant and culturally interesting stay in Friuli-Venezia Giulia.

Paolo M. Fioretti  
*President of the 12<sup>th</sup> Alpe Adria Cardiology Meeting*

### **CONGRESS PRESIDENT**

P. M. Fioretti, MD, FESC, FACC, PhD

### **ORGANIZED BY THE DEPARTMENT OF CARDIO- VASCULAR SCIENCES, S. MARIA DELLA MISER- ICORDIA HOSPITAL, UDINE**

U. Livi, MD

Head, Department of Cardiovascular Sciences

Head, Cardiothoracic Surgery

P. M. Fioretti, MD, PhD

Head, Cardiology

L. Mozzon, MD

Head, Vascular Surgery

### **Scientific Secretary**

C. Fresco, MD

### **Local SCIENTIFIC Committee**

P.M. Fioretti (Chair)

C. Fresco (Co-Chair)

A. Proclemer

L. Badano

G. Bernardi

M.C. Albanese

D. Vanuzzo

A. Di Chiara

Department of Cardiovascular Sciences

S. Maria della Misericordia Hospital

Udine, Italy

*in cooperation with IRCAB Foundation – Udine*

**INTERNATIONAL ADVISORY BOARD**

J. Borbola (Hungary)  
 R. Cerbak (Czech Republic)  
 B. Cibic (Slovenia)  
 I. Cikes (Croatia)  
 M. Csanady (Hungary)  
 S. Dalla Volta (Italy)  
 J. Fabian (Slovakia)  
 F. Furlanello (Italy)  
 G. Ghironzi (S. Marino)  
 R. Hatala (Slovakia)  
 J. Hradec (Czech Republic)  
 K. Huber (Austria)  
 M. F. Kenda (Slovenia)  
 W. Klein (Austria)  
 D. Milicic (Croatia)  
 D. Petrac (Croatia)  
 I. Preda (Hungary)  
 P. Rakovec (Slovenia)  
 I. Riecansky (Slovakia)  
 J. Spinar (Czech Republic)  
 K. Steinbach (Austria)

**Under the Patronage of**

Regione Autonoma Friuli-Venezia Giulia  
 A.N.M.C.O. Nazionale  
 IRCAB Foundation - Udine  
 Azienda Ospedaliera Santa Maria della Misericordia,  
 Udine  
 Comunit  di Lavoro Alpe Adria della Regione Autonoma  
 Friuli-Venezia Giulia  
 Provincia di Udine  
 Camera di Commercio Industria, Artigianato e Agricoltura  
 di Udine  
 Comune di Cividale del Friuli (UD)  
 Banca di Cividale del Friuli (UD)  
 Servier Slovakia

**Thursday 29 April**

<b>Room A</b>	<b>Room B</b>
<p><b>Session 1</b>  <b>9.00–10.45</b></p> <p><b>Pharmacoinvasive treatment of STEMI</b></p> <p><i>Chair: M.F. Kenda (Slo), G. Guarnieri (I)</i></p> <ol style="list-style-type: none"> <li>1. M. Noc (Slo) – Treatment of STEMI in Ljubljana region with primary PCI</li> <li>2. C. Fresco (I) – Potential benefits and pitfalls of facilitated PCI</li> <li>3. F. Weidinger (A) – Treatment of STEMI in rural areas with long transfer time. current strategies</li> <li>4. I. Kranjec (Slo) – Experience with late presenters in Slovenia</li> <li>5. H. Schuhlen (D) – Experience with late presenters in Bavaria</li> </ol>	<p><b>Session 2 (Room B)</b>  <b>9.00–10.45</b></p> <p><b>Pharmacological and non pharmacological treatment of heart failure</b></p> <p><i>Chair: S. Dalla Volta (I), J. Spinar (CZ)</i></p> <ol style="list-style-type: none"> <li>1. J. Spinar (CZ) – Pathophysiology and treatment of diastolic heart failure</li> <li>2. D. Milicic (Hr) - Drugs and devices for cardiovascular continuum</li> <li>3. A. Di Lenarda (I) – Long term follow up of dilated cardiomyopathies</li> <li>4. C.A. Beltrami (I) – Stem cells technology for cardiac repair</li> <li>5. A. Bohm (H) – Biventricular pacemaker treatment</li> </ol>

**Thursday 29 April**

<b>Room A</b>	<b>Room B</b>
<p><b>Session 3</b> <b>11.00–12.45</b></p> <p><b>Aggressive antithrombotic treatment of NSTEMI inside and outside the cath lab</b></p> <p><i>Chair: K. Huber (A), D. Milicic (Hr)</i></p> <ol style="list-style-type: none"> <li>1. F.A. Nicolini (S Marino) – Basic science concepts of ACS</li> <li>2. C. Fresco (I) – The role of clopidogrel in ACS</li> <li>3. K. Huber (A) – Antithrombotic therapy in diabetic patients with ACS</li> <li>4. M. Bergovec (Hr) IIb/IIIa – inside and outside the cath lab</li> <li>5. C. Cavallini (I) – Post PCI prognostic stratification: CK release study</li> </ol>	<p><b>Session 4</b> <b>11.00–12.45</b></p> <p><b>Atrial fibrillation between catheters and drugs</b></p> <p><i>Chair: P. Delise (I) , K. Steinbach (A)</i></p> <ol style="list-style-type: none"> <li>1. A. Smalcelj (Hr) – Evidence based management – do we need new guidelines?</li> <li>2. P. Rakovec (Slo) – Pacemakers for management of atrial fibrillation</li> <li>3. M. Disertori (I) – Indications for trans catheter ablation</li> <li>4. R. Cappato (I) – Long term outcome after trans catheter ablation</li> <li>5. D. Petrac (Hr) – Rhythm vs rate control</li> <li>6. R. Mantovan (I) – Surgical ablation of atrial fibrillation</li> </ol>
<p><b>Session 5</b> <b>14.00–16.00</b></p> <p><b>New imaging techniques</b></p> <p><i>Chair: J. Fabian (SK) , S. Iliceto (I)</i></p> <ol style="list-style-type: none"> <li>1. H. Frank (A) – The role of MRI in cardiac diseases, year 2004</li> <li>2. S. Iliceto (I) – Assessment of coronary reperfusion by MRI</li> <li>3. E. Mazzaro (I) – Video guided mitral valve surgery</li> </ol>	<p><b>Session 6</b> <b>14.00–16.00</b></p> <p><b>Clinical cases on heart failure</b></p> <p><i>Chair: M.C. Albanese (I), A. Di Lenarda (I)</i></p> <p><b>Clinical cases:</b> M.C. Albanese (I) A. Di Lenarda (I)</p> <p><b>Lecture:</b> M. Dekany (H) – Spironolactone treatment in heart failure in the typical heart failure population. Caution is necessary</p>
<p><b>16.30–18.00</b></p> <p><b>OPENING CEREMONY</b> <b>P.M. Fioretti</b></p> <p><b>OPENING LECTURE</b> <b>H. Saner (CH) – From cardiovascular rehabilitation to prevention: a European perspective</b></p>	

**Friday 30 April**

<b>Room A</b>	<b>Room B</b>
<p><b>Session 7</b> <b>9.00–10.45</b></p> <p><b>New frontiers of echocardiography</b></p> <p><i>Chair: G.L. Nicolosi (I), I. Cikes (Hr)</i></p> <ol style="list-style-type: none"> <li>1. T. Forster (H) – Prognostic impact of echocardiography on ischaemic heart disease</li> <li>2. H. von Bibra (D) – Subclinical cardiac dysfunction in diabetic patients</li> <li>3. R. Rosenhek (A) – New indications for aortic valve surgery based on echocardiographic results</li> <li>4. F. Antonini Canterin (I) – Non invasive assessment of aortic valve stenosis</li> <li>5. B. Pinamonti (I) – Mitral valve regurgitation in dilated cardiomyopathy</li> </ol>	<p><b>Session 8</b> <b>9.00–10.45</b></p> <p><b>Free communications</b></p> <p><i>Chair: I. Preda (H), B. Cibic (Slo)</i></p> <ol style="list-style-type: none"> <li>1. T. Winter (A) – Optimized programming of the ventricular-ventricular interval increases stroke volume in patients with biventricular pacing</li> <li>2. S. Manola (Hr) – Evaluation of risk factors and therapeutic approach to patients with acute coronary syndromes in coronary care unit of sestre milosrdnice University Hospital 1999-2003</li> <li>3. Riecanaky (SK) – Coronary heart disease and abdominal aortic aneurysm</li> <li>4. M. Poloczek (CZ) – The early ST segment resolution and the prediction of the left ventricle remodeling in patients with acute myocardial infarction</li> <li>5. M. Lainscak (Slo) – No effect of coronary revascularisation on return on return to work in patients with acute coronary syndrome</li> <li>6. P. Trcka (CZ) – Heart rate turbulence in risk stratification of sudden cardiac death – a prospective study</li> <li>7. K. Havasi (H) – Usefulness of routine scanning of the thoracic aorta during transesophageal echocardiography</li> <li>8. M. Frick (A) – brachial artery intima-media thickness is closely related to long-term cardiovascular events</li> <li>9. Benettoni (I) – Adult patients with congenital heart disease: reasons for specialised cardiological service</li> <li>10. J. Semenska (CZ) – The 4 years clinical and angiographical follow-up in patients with acute myocardial infarction (AMI), treated with immediate thrombolysis v.s. primary angioplasty vs combined strategy. Single center randomized trial, subgroup of PRAGUE study</li> </ol>

## Friday 30 April

### Room A

#### Session 9

11.00–12.45

#### Implications of recently reported large scales clinical trials and registries

*Chair: G. Ghironzi (SM), M. Csadany (H)*

1. I. Preda (H) – Hypertension in the IMPROVEMENT HF population
2. R. Latini (I) – The VALIANT study
3. A. Di Chiara (I) – Recent Italian surveys in ACS (the Blitz studies)
4. A. Desideri (I) – The EuroAction trial
5. K. Steinbach (A) – The Austrian AMI Registry

### Room B

#### Session 10 (Room B)

11.00–12.45

#### Free communications

*Chair: I. Riečanský (SK), P. Rakovec (Slo)*

1. M. Sluka (CZ) – Primary PCI in patients with acute myocardial infarction complicated by cardiogenic shock requiring intraaortic balloon contrapulsation
2. R. Pecoraro (I) – Optimal pharmacotherapy after myocardial infarction does not mean adequate risk factor control in the Real World of Busy Cardiologists
3. A. Antovski (MK) – C-reactive protein as a marker of severity of chronic heart failure
4. R. Pudil (CZ) – Plasma N-Terminal pro brain natriuretic peptide (NT-PRO BNP) and clinical parameters in patients with left ventricular dysfunction
5. V. Kutyifa (H) – Reduction of coronary flow reserve predicts mortality in coronary artery disease. A transesophageal echocardiography study
6. B. Stanek (A) – Comparison of soluble glycoprotein 130 with cardiac natriuretic peptides as longterm predictors in patients with severe left ventricular dysfunction
7. A. Bertoldi (I) – Life threatening sustained ventricular tachycardias in Elite Athletes with apparently intact heart
8. L. Hodacova (CZ) – Trends in mortality from diseases of circulatory system in the Czech Republic
9. H. Balint (H) – Assessment of the predictive value of transesophageal echocardiography before transcatheter closure of ostium secundum atrial septal defect in adults

**Friday 30 April**

<b>Room A</b>	<b>Room B</b>
<p><b>Session 11</b> <b>14.00–15.45</b></p> <p><b>Risk factors for secondary prevention</b></p> <p><i>Chair: L. Sechi (I), D. Vanuzzo (I)</i></p> <ol style="list-style-type: none"> <li>1. Z. Fras (Slo) – Comprehensive risk prediction of atherosclerosis related diseases</li> <li>2. R. Kiss (H) – Secondary prevention in atherothrombosis</li> <li>3. R. Latini (I) – Biomarkers guided prognostic stratification in CHF and AMI</li> <li>4. Z. Reiner – Antibiotics in secondary prevention of coronary artery disease</li> <li>5. E. Trautwein (NL) – The power of nutrition for the healthy heart</li> </ol>	<p><b>Session 12</b> <b>14.00–15.45</b></p> <p><b>New surgical options</b></p> <p><i>Chair: U. Livi (I), R. Cerbak (CZ)</i></p> <ol style="list-style-type: none"> <li>1. T. Klokocovnik (Slo) – Revascularization on beating heart</li> <li>2. R. Cerbak (CZ) – Valvular heart surgery in the elderly</li> <li>3. U. Livi (I) – Prognosis and quality of life after cardiac transplantation</li> <li>4. L. Spinarova (CZ) – Heart transplantation programs in Eastern Europe</li> <li>5. F. Cademartiri (NL) – Coronary imaging by multi-slice CT</li> </ol>
<p><b>Session 13</b> <b>16.00–17.30</b></p> <p><b>Interventional cardiology in the drug eluted stents era</b></p> <p><i>Chair: G. Morocutti (I), T. Forster (H)</i></p> <ol style="list-style-type: none"> <li>1. V. Fridrich (SK) – Role of DES in coronary percutaneous interventions, a Central European Perspective</li> <li>2. G. Gaul (A) – Cost effectiveness of DES</li> <li>3. G. Bernardi (I) – Are “conventional” stents really obsolete?</li> <li>4. E. Margetic: IVUS-guided coronary interventions in the drug eluting stents era</li> </ol> <p><b>Lecture:</b> E. Arbustini (I) – Can molecular genetics contribute to treatment options?</p>	<p><b>Session 14</b> <b>16.00–17.30</b></p> <p><b>Clinical cases on echocardiography and non invasive coronary angiography (multislice CT scan)</b></p> <p><i>Chair: L. Badano (I), D. Gasparini (I)</i></p> <ol style="list-style-type: none"> <li>1. P. Gianfagna (I) – Echocardiography</li> <li>2. G. Slavich (I) – Nuclear cardiology</li> <li>3. R. Cademartiri (NL) – Clinical examples of multi-slice CT coronary angiography</li> </ol>
<p><b>19.30 Social Event</b></p>	

**Saturday 1<sup>st</sup> May**

<b>Room A</b>	<b>Room B</b>
<p><b>Session 15</b> <b>9.00–10.30</b></p> <p><b>MADIT 2 implications in the ALPE ADRIA region</b></p> <p><i>Chair: A. Raviele (I), D. Petrac (Hr)</i></p> <ol style="list-style-type: none"><li>1. R. Hatala (SK) – Primary prevention of sudden cardiac death – is evidence based medicine sustainable with budget restrictions?</li><li>2. J. Borbola (H) – The incidence of MADIT patients in the ICD registry of the National Institute of Cardiology in Hungary</li><li>3. A. Proclemer (I) – SEARCH MI trial: South European Survey of MADIT 2</li><li>4. A. Podczeck (A) – Implications of MADIT 2 in Austria</li></ol>	
<p><b>Session 16</b> <b>10.45-12.15</b></p> <p><b>Final Lectures</b></p> <p><i>Chair: P.M. Fioretti (I), S. Dalla Volta (I)</i></p> <ol style="list-style-type: none"><li>1. F. Furlanello (I) – Arrhythmogenic effects of illicit drugs in athletes</li><li>2. G. Thiene (I) – Myocarditis in the era of molecular diagnosis</li><li>3. S. Dalla Volta (I) - Closing Remarks</li></ol>	